We use cookies to give you the best personal experience on our website. If you continue to use our site without changing your cookie settings, you agree we may place these cookies on your device. You can change your cookie settings at any time but if you do , you may lose some functionality on our website . More information can be found in our privacy policy.
Please provide more information.
Stylus no longer supports Internet Explorer 7, 8 or 9. Please upgrade to IE 11, Chrome, Safari, Firefox or Edge. This will ensure you have the best possible experience on the site.
Brief Published: 19 Oct 2012

Anti-Cancer Vaccine

Extra

Israeli pharmaceutical company Vaxil BioTherapeutics has created a therapeutic vaccine with the potential to treat cancerous cells and prevent them from coming back.

The newly developed vaccine, ImMucin, uses a molecule called MUC1 – found in 90% of cancers – to train the human immune system to recognise and destroy rogue cells.

A company spokesman said that the first trial “generated a robust and specific immune response in all patients, which was observed after only two or four doses of the vaccine”.

The formula is undergoing clinical trials in Hadassah University Medical Centre in Jerusalem and could be available by 2017.

Vaxil BioTherapeutics

PANTONE®TPX
COATED
RAL
RGB
HEX
NCS